<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bevacizumab a recombinant humanized monoclonal antibody was approved in 2004 by US FDA for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It is reported to cause potentially serious toxicities including severe <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To correlate adverse event <z:hpo ids='HP_0001281'>tetany</z:hpo> with the use of bevacizumab </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: World Health Organization's Uppsala Monitoring Centre, Sweden, for reporting of adverse drug reactions from <z:hpo ids='HP_0000001'>all</z:hpo> over the world, identified 7 cases with <z:hpo ids='HP_0001281'>tetany</z:hpo>-related symptoms to bevacizumab from four different countries </plain></SENT>
<SENT sid="4" pm="."><plain>These 7 patients reported to UMC database developed adverse events described as musculoskeletal stiffness (1), <z:mp ids='MP_0000743'>muscle spasm</z:mp> (1), <z:hpo ids='HP_0003394'>muscle cramps</z:hpo> (1), lock jaw or jaw stiffness (4), and <z:hpo ids='HP_0001276'>hypertonia</z:hpo> (1), with <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After detailed study of the possible mechanism of actions of bevacizumab and factors causing <z:hpo ids='HP_0001281'>tetany</z:hpo>, it is proposed that there is a possibility of <z:hpo ids='HP_0001281'>tetany</z:hpo> by bevacizumab, which may occur by interfering with calcium metabolism </plain></SENT>
<SENT sid="6" pm="."><plain>Resorption of bone through osteoclasts by affecting VEGF may interfere with calcium metabolism </plain></SENT>
<SENT sid="7" pm="."><plain>Another possibility of <z:hpo ids='HP_0001281'>tetany</z:hpo> may be due to associated hypomagnesaemia, <z:hpo ids='HP_0002900'>hypokalemia</z:hpo>, or <z:hpo ids='HP_0002902'>hyponatremia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0001281'>Tetany</z:hpo> should be considered as a one of the signs </plain></SENT>
<SENT sid="9" pm="."><plain>Patient on bevacizumab should carefully watch for <z:hpo ids='HP_0001281'>tetany</z:hpo>-related symptoms and calcium and <z:chebi fb="131" ids="25107">magnesium</z:chebi> levels for their safety </plain></SENT>
</text></document>